Table 3.
Differences in the Presentation and Outcomes between Black, Latino, and API Patients with AIH
| Measurements | Total (n = 58) |
Black (n = 10) |
Latino (n = 29) |
API (n = 19) |
p-values |
|---|---|---|---|---|---|
| Presentation | |||||
| ALT (U/L) | 198 | 308 | 182 | 189 | 0.45 |
| IgG (mg/dL) | 2040 | 2988 | 1960 | 1895 | 0.12 |
| ANA | 1:640 | 1:640 | 1:640 | 1:640 | 0.93 |
| ASMA | 32 | 63 | 37 | 20 | 0.11 |
| AMA | 5.7 | 8.3 | 5.1 | 5.9 | 0.98 |
| INR | 1.2 | 1.3 | 1.1 | 1.1 | 0.58 |
| Total Bilirubin (mg/dL) | 0.8 | 2.8 | 0.7 | 1.1 | 0.06 |
| Biopsy Inflammation Grade* | 2.8 | 3.1 | 2.8 | 2.4 | 0.09 |
| Biopsy Fibrosis Stage* | 2.1 | 2.2 | 2.2 | 1.9 | 0.74 |
| Biopsy Steatosis Grade* | 0.1 | 0.0 | 0.1 | 0.2 | 0.65 |
| Treatment/Outcomes | |||||
| ALT 6 mo. after Treatment Initiation (U/L) | 38 | 33 | 46 | 31 | 0.20 |
| Hospitalization (%) | 39.3 | 60.0 | 39.3 | 27.8 | 0.27 |
| Decompensation (%) | 18.2 | 20.0 | 14.3 | 23.5 | 0.65 |
| Concomitant Autoimmune Disease (%) | 35.4 | 50.0 | 30.8 | 35.7 | 0.65 |
| Budesonide Use (%) | 10.3 | 10.0 | 13.8 | 5.3 | 0.85 |
| Mycophenolate Use (%) | 10.3 | 20.0 | 13.8 | 0.0 | 0.11 |
| Time from Diagnosis to Treatment (Days) | 13.0 | 3.0 | 34.5 | 9.5 | 0.11 |
*
Mean values presented; all other values are median values unless otherwise designated.